Scientists share promising COVID-19 drug development breakthrough

Infectious disease scientists at the University of Pittsburgh and University of Pittsburgh Medical Center (UPMC) have shared details of a promising breakthrough in COVID-19 drug development.

Before this strain of coronavirus became a widespread concern in the US, experts at both organisations rapidly mobilised to look for a treatment.

Researchers at Pitt’s Centre for Antibody Therapeutics, with support from UPMC, panned their library of 100 billion antibodies to identify possible candidates for use against SARS-CoV-2 (the virus that causes COVID-19).

Using the SARS-CoV-2 spike protein as bait, Dr Dimiter Dimitrov and his team had identified the most promising options in barely a week, and they used one of them to create a drug now called Ab8.

Dr John Mellors, UPMC and Pitt’s chief of infectious diseases, and Dimitrov, Director of the Center for Antibody Therapeutics, collaborated with several universities throughout the United States and Canada to further study Ab8 with the hope that it can one day serve as both a treatment and a preventative measure against COVID-19.

The findings from their initial research were recently published in the journal Cell.

“This team approach to science is critical to addressing COVID-19 because it is a global challenge facing all of humanity,” said Dimitrov.

“I am proud that Pittsburgh is playing such a key role in the efforts of biomedical science and human ingenuity to overcome this pandemic.”

Abound Bio, a recently formed UPMC-backed company, has licensed Ab8 for worldwide development.

“This advance—like all of our other advances during the pandemic—came quickly because we laid the groundwork long ago and took risks and made investments that few other academic medical centers would make,” said Shapiro, UPMC’s Chief Medical and Scientific Officer.

“There is still much work to be done to make this antibody-based drug available to patients, but this is an exciting and promising advance as we work on multiple strategies to end this pandemic.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...

Moderna regains rights to RSV vaccine from Merck

Moderna has regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. mRNA-1172,...

Takeda & Arrowhead to co-develop RNAi therapy for AATLD

Takeda and Arrowhead Pharmaceuticals will collaborate to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver...

Related news

CHMP recommends ViiV’s long-acting regimen for HIV

The Committee for Medicinal Products for Human Use (CHMP) has recommended ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in combination with Rekambys (rilpivirine injection)...

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...